Modality
Nanobody
MOA
DLL3 ADC
Target
PLK4
Pathway
STING
NSCLCHuntington'sPSP
Development Pipeline
Preclinical
~Dec 2022
→ ~Mar 2024
Phase 1
~Jun 2024
→ ~Sep 2025
Phase 2
Dec 2025
→ Oct 2029
Phase 2Current
NCT06308935
891 pts·PSP
2025-12→2029-10·Active
891 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2029-10-273.6y awayPh2 Data· PSP
Trial Timeline
2026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q4
P2
Active
Catalysts
Ph2 Data
2029-10-27 · 3.6y away
PSP
Active|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06308935 | Phase 2 | PSP | Active | 891 | HbA1c |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| NVS-4076 | Novartis | Preclinical | TROP-2 | |
| Rimamavacamten | Merck & Co | Phase 1 | PI3Kα | |
| AMG-9654 | Amgen | Phase 2 | GPRC5D | |
| Bemanesiran | BioNTech | Phase 3 | PLK4 | |
| Peminaritide | Sarepta | NDA/BLA | PLK4 | |
| Pexaosocimab | United Therapeutics | NDA/BLA | PLK4 | |
| Polalucimab | Jazz Pharma | Preclinical | PLK4 | |
| ILM-2412 | Illumina | Phase 3 | PLK4 | |
| ROI-3353 | Roivant Sciences | Phase 1/2 | PLK4 | |
| Tixatapinarof | Arvinas | Phase 1/2 | CDK2 |